Akron Biotech has signed an exclusive global agreement with Switzerland-based Octapharma to produce virally inactivated Human AB Serum for the cell therapy market using the latter’s Octaplas.
Fresenius Kabi has decided to terminate the company’s previously announced merger agreement with Akorn, a United States-based manufacturer and marketer of prescription and over-the-counter pharmaceutical products.